Cellivery's Atopic Dermatitis Treatment New Drug Ointment iCP-NI... "Efficacy Evaluation Test Begins in the US"

[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 14th that it has begun efficacy evaluation tests at the global contract research organization MLM Medical Labs for 'iCP-NI,' an intrinsic immune-regulating COVID-19 immunotherapy drug under development in the United States, to develop it as a new treatment drug for the intractable autoimmune disease atopic dermatitis.

Atopic dermatitis, an intractable autoimmune disease, is not a simple skin condition but a chronic inflammatory immune disease caused by disruption of the body's immune system. It occurs in various parts of the body and causes unbearable itching. Symptoms caused by abnormally overactivated immune responses and damage to the skin barrier continuously recur, causing lifelong cycles of recovery and exacerbation. Patients with severe atopic dermatitis suffer from serious itching, rashes, and eczema, leading to sleep disorders, avoidance of outdoor activities, and reluctance to form interpersonal relationships, severely impairing their quality of life.

iCP-NI, which has an excellent intrinsic immune-regulating pharmacological mechanism, is currently preparing to enter clinical trials in the United States as a treatment for COVID-19 infectious disease and sepsis. To expand indications, therapeutic efficacy was verified in an inflammatory skin disease animal model mimicking atopy, showing treatment efficacy sufficient for clinical development. Development is currently underway in Europe and the United States.

A company official stated, "In the skin tissue of the atopy animal model, iCP-NI reduced inflammatory immune T cells by more than 50%," adding, "It also showed strong anti-inflammatory and anti-atopic therapeutic effects by reducing the secretion of the most potent inflammatory cytokines TNF-alpha (TNF-α), interleukin-6 (IL-6), and immunoglobulin E (IgE), which causes allergic reactions, by 87%, 66%, and 71%, respectively." He further added, "It was analyzed that the thickened skin and damaged skin barrier caused by continuous inflammatory responses were restored by more than 60%."

Daewoong Cho, CEO of Cellivery, emphasized, “The successful production of the ointment formulation of iCP-NI and the start of therapeutic efficacy evaluation tests signify a step forward in the development of a 'topical autoimmune treatment new drug.'”